• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Aurora Cannabis Announces Appointment of New Director

    5/15/24 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

     NASDAQ | TSX: ACB 

    Newly created directorship to be filled by Rajesh Uttamchandani

    EDMONTON, AB, May 15, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the "Board"), effective today.

    Aurora Cannabis Inc. Logo (CNW Group/Aurora Cannabis Inc.)

    Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leading businesses in emerging technology, FinTech, human capital consulting and global education. Most recently, he was the Chief People Officer for ApplyBoard, an organization recognized as one of the fastest-growing technology companies in Canada. Previous roles include serving as Chief Operating Officer and Chief People Officer at MaRs Discovery District, North America's largest urban innovation hub committed to advancing companies during their prime periods of growth and Chief Human Resources Officer and Managing Director at Zafin, a Global FinTech supporting modernization of the world's Tier-1 banks.

    "I am very pleased to be welcoming Raj to our Board of Directors. He brings a breadth of knowledge and capability from a variety of sectors and disciplines that will undoubtedly be additive to Aurora and complement the existing strength of our Board. As we pursue our objective to achieve sustainable performance and global leadership in the cannabis market, we will benefit from Raj's experience in human capital, strategy and innovation – all of which are woven into our strategic priorities – as well as from his past and current directorships," said Ron Funk, Chairman of Aurora Cannabis.

    Mr. Uttamchandani brings to Aurora a wealth of experience as current and past Director for private and public organizations, including LifeSpeak, Ontario Cannabis Stores, Mackenzie Health, and several not-for-profit organizations. Mr. Uttamchandani holds several degrees and professional designations, including a Master of Industrial Relations and Human Resources from University of Toronto; a Juris Doctor from Osgoode Hall Law School; and an L.L.M in Employment and Labour, also from Osgoode Hall Law School. He is a holder of the Institute of Corporate Directors Director designation (ICD.D) and is a lawyer called to the Bar of Ontario.

    About Aurora Cannabis  

    Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.  

    Forward-looking Information 

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the appointment of a new director to the Company's Board of Directors and associated benefits, and the Company's plans to achieve sustainable performance and global leadership in the cannabis market.

    These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 14, 2023 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-appointment-of-new-director-302145765.html

    SOURCE Aurora Cannabis Inc.

    Get the next $ACB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Aurora Cannabis

      TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

      12/11/24 10:35:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

      2/9/24 6:09:16 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

      9/21/22 9:02:55 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

      VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

      5/15/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

      NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

      9/20/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

      NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

      8/12/24 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    SEC Filings

    See more
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      7/24/25 1:17:56 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      7/14/25 7:23:33 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Aurora Cannabis Inc.

      6-K - AURORA CANNABIS INC (0001683541) (Filer)

      7/9/25 4:55:48 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aurora Cannabis to Host First Quarter 2026 Investor Conference Call

            NASDAQ | TSX: ACB EDMONTON, AB, July 23, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its first quarter 2026 on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the first quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, August 6, 2025 TIME: 8:00 a.m. Easte

      7/23/25 5:35:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Completes First-Ever EU-GMP Certification for the Company's Dedicated Distribution Centre

      Adding a fourth certified facility within its global network increases operational capacity to better serve international medical markets NASDAQ | TSX: ACB EDMONTON, AB, July 14, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that its dedicated distribution centre located in Brampton, Ontario, has received European Union Good Manufacturing Practice ("EU-GMP") certification, increasing the company's international export capabilities. The distribution centre joins Aurora's group of manufacturing facilities in Canada and Europe certified against EU standards, demonstrating the company's unwaveri

      7/14/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Inc. Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General and Special Meeting of Shareholders

      Your vote is important no matter how many shares you own. Please vote today.Shareholders who have questions or need assistance with voting their shares should contact Aurora's strategic advisor and proxy solicitation agent, Laurel Hill Advisory Group, by telephone at 1-877-452-7184 or by email at [email protected], AB, July 9, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce that the management information circular (the "Circular") for the upcoming annual general and special meeting of shareholders is now available on the Company's website at www.auroram

      7/9/25 7:30:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/23 11:28:04 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Aurora Cannabis Inc.

      SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

      6/1/22 10:14:29 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

      SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

      2/14/22 3:54:29 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care

    $ACB
    Financials

    Live finance-specific insights

    See more
    • Aurora Cannabis to Host First Quarter 2026 Investor Conference Call

            NASDAQ | TSX: ACB EDMONTON, AB, July 23, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its first quarter 2026 on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the first quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, August 6, 2025 TIME: 8:00 a.m. Easte

      7/23/25 5:35:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter

       NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue1 of $244.4 million, representing 39% YoY growthDelivers Record Adjusted EBITDA1 of $49.7 million, representing 261% YoY growthGenerates Annual Positive Free Cash Flow1 of $9.9 million Sustains Strong Balance Sheet with ~$185.3 million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025.

      6/18/25 7:00:00 AM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care
    • Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2025 Investor Conference Call and File Related Year End Information

      NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025

      6/3/25 4:15:00 PM ET
      $ACB
      Medicinal Chemicals and Botanical Products
      Health Care